Back to top
more

NxStage Medical, Inc. (NXTM)

(Delayed Data from NSDQ)

$30.00 USD

30.00
NA

0.00 (0.00%)

Updated Feb 21, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

4 Healthcare Stocks Likely to Beat Estimates in Q4

by Zacks Equity Research

An aging population, prevalence of chronic health conditions and greater utilization of healthcare services should drive the industry's growth, partly offset by an increase in expenses.

4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

by Zacks Equity Research

Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.

NxStage Medical (NXTM) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

NxStage (NXTM) delivered earnings and revenue surprises of 150.00% and 0.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Will NxStage Medical (NXTM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

NxStage (NXTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NxStage Medical (NXTM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

NxStage (NXTM) delivered earnings and revenue surprises of 20.00% and 1.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Medical Product Stock Earnings on Aug 6: CAH, HSIC & More

    by Zacks Equity Research

    The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.

      NxStage Nx2me Connected Health Improves Home Hemodialysis

      by Zacks Equity Research

      NxStage Medical (NXTM) consistently looks to expand dialysis platform.

        Here's Why You Should Offload Fresenius Medical Stock Now

        by Zacks Equity Research

        Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.

          Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact

          by Zacks Equity Research

          Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.

            NxStage System One Gets FDA Nod for Solo Home Hemodialysis

            by Zacks Equity Research

            The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.

              NxStage Medical Partners Dialyze Direct for On-Site Dialysis

              by Zacks Equity Research

              The latest development will lend NxStage Medical (NXTM) a competitive edge in the hemodialysis dialysis market. The company will leverage on its System One platform for treating patients with ESRD.

                Fresenius Medical Inks $2B Deal to Take Over NxStage Medical

                by Zacks Equity Research

                Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.

                  Company News For August 08, 2017

                  by Zacks Equity Research

                  Companies in the news are: TSN,COL,UTX,TEVA,NXTM

                    Megan Sanks headshot

                    NxStage (NXTM) Jumps 28% on $2 Billion Acquisition by FMS

                    by Megan Sanks

                    German dialysis provider Fresenius Medical Care (FMS) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. (NXTM) for $2 billion.

                      NxStage Medical: NxGen Hemodialysis System Now CE Marked

                      by Zacks Equity Research

                      NxStage Medical, Inc. (NXTM) recently announced the receipt of CE mark for its NxGen Hemodialysis System, an innovative device with easier user interface and integrated blood pressure monitor system for patients performing home hemodialysis.

                        Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay

                        by Zacks Equity Research

                        Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.

                          IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index

                          by Zacks Equity Research

                          IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.

                            Illumina Fettered With Losses: Can It Bounce Back in 2017?

                            by Zacks Equity Research

                            During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.

                              Masimo to Launch Advanced Monitoring Technologies in India

                              by Zacks Equity Research

                              Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.

                                OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3

                                by Zacks Equity Research

                                OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.

                                  Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?

                                  by Zacks Equity Research

                                  On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).

                                    Is Baxter Poised to Counter Low Cyclophosphamide Sales?

                                    by Zacks Equity Research

                                    On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

                                      CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions

                                      by Zacks Equity Research

                                      On Dec 27, CryoLife Inc. (CRY) was upgraded to a Zacks Rank #1 (Strong Buy).

                                        Alere (ALR) Appeals to Reinstate Medicare Billing Privilege

                                        by Zacks Equity Research

                                        Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.

                                          NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite

                                          by Zacks Equity Research

                                          NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.